Last reviewed · How we verify
Neoadjuvant Treatment of Breast Cancer - a Prospective Observational Study, PANnon ONCology (PANONC) Group Non-commercial Clinical Trial
Observational investigation of participants who are given neoadjuvant treatment for invasive breast cancer. The scope of the study is to collect information on standardized treatment results, to explore the causes of dose modification and its effect on efficacy, to explore potential prognostic factors, and to explore the long-term side effects of different treatment modalities.
Details
| Lead sponsor | National Institute of Oncology, Hungary |
|---|---|
| Status | NOT_YET_RECRUITING |
| Enrolment | 300 |
| Start date | 2022-03 |
| Completion | 2031-12 |
Conditions
- Breast Cancer
Interventions
- Tamoxifen
- Goserelin
- Letrozole 2.5Mg Tab
- Epirubicin
- cyclophosphamide
- Docetaxel
- paclitaxel
- trastuzumab
- pertuzumab
- Capecitabine
Primary outcomes
- pathological complete remission rate — 3 year, maximum
no invasive tumor in breast and axilla
Countries
Hungary